Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (4) : 426-430    https://doi.org/10.1007/s11684-009-0085-7
Research articles
Expression of PC-cell-derived growth factor in breast cancer
Haiping SONG MD,Lan SHI MD,Chunping LIU MD,Tao HUANG MD,
Thyroid and Breast Surgical Center, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, China;
 Download: PDF(119 KB)  
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract This study is mainly aimed at evaluating the expression of PC-cell-derived growth factor (PCDGF) in breast cancer and breast adenofibroma, and to compare with other commonly used clinical pathological indices, then to investigate the diagnostic and targeted therapeutic purpose of PCDGF in breast cancer tissue. In this study, we detected the expression of PCDGF, p53 and CerbB-2 in breast cancer tissue and the expression of PCDGF in breast adenofibroma tissue by immunohistochemical method, and analyzed the relationship between them. We found that PCDGF was expressed in most breast cancer tissue, but was not in breast adenofibroma tissue, and the expression of PCDGF was related with the tumor’s pathological category and the expression of estrogen receptor (ER) and progesterone receptor (PR) and p53, but there was no statistical dependability between PCDGF and cerbB-2. From this study, we predict that PCDGF may serve as a marker in the secondary diagnosis of breast cancer, and may participate in the generation and differentiation of breast cancer cells, and become an effective target of therapy for breast cancer.
Keywords PC-cell-derived growth factor      breast neoplasms      clinical markers      
Issue Date: 05 December 2009
 Cite this article:   
Haiping SONG MD,Chunping LIU MD,Lan SHI MD, et al. Expression of PC-cell-derived growth factor in breast cancer[J]. Front. Med., 2009, 3(4): 426-430.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0085-7
https://academic.hep.com.cn/fmd/EN/Y2009/V3/I4/426
Hoskins K, Weber B L. The biology of breast cancer. Curr Opin Oncol, 1994, 6(6): 554―559

doi: 10.1097/00001622-199411000-00004
Reiss K, Valentinis B, Tu X, Xu S Q, Baserga R. Molecular markers of IGF-I-mediated mitogenesis. Exp Cell Res, 1998, 242(1): 367―372

doi: 10.1006/excr.1998.4113
Tangkeangsirisin W, Serrero G. PC cell-derived growth factor(PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGFexpression in breast cancer cells. Carcinogenesis, 2004, 25(9): 1587―1592

doi: 10.1093/carcin/bgh171
Zanocco-Marani T, Bateman A, Romano G, Valentinis B, He Z H, Baserga R. Biological activities and signaling pathways of the granulin/epithelinprecursor. Cancer Res, 1999, 59(20): 5331―5340
Tangkeangsirisin W, Hayashi J, Serrero G. PC cell-derived growth factor mediates tamoxifen resistanceand promotes tumor growth of human breast cancer cells. Cancer Res, 2004, 64(5): 1737―1743

doi: 10.1158/0008-5472.CAN-03-2364
Lu R Q, Serrero G. Inhibition of PC cell-derivedgrowth factor (PCDGF, epithelinygranulin precursor) expression byantisense PCDGF cDNA transfection inhibits tumorigenicity of the humanbreast carcinoma cell line MDA-MB-468. PNAS, 2000, 97(8): 3993―3998

doi: 10.1073/pnas.97.8.3993
Kuang S Q, Liao L, Zhang H, Lee A V, O’Malley B W, Xu J M. AIB1/SRC-3 deficiency affects insulin-like growth factorI signaling pathway and suppresses v-Ha-ras-induced breast cancerinitiation and progression in mice. CancerRes, 2004, 64(5): 1875―1885

doi: 10.1158/0008-5472.CAN-03-3745
Shi L, Song H P, Liu C P, Huang T. Effect of PC-cellderived growth factor shRNA on estrogen dependent of estrogen receptornegative breast cancer cell lines. ZhonghuaWai Ke Za Zhi, 2007, 45(7): 483―486 (in Chinese).
Huang T, Song H P, Zhang J H. Effect of PCDGF shRNA on growth, proliferation, apoptosisof human breast carcinoma cell line MCF-7 and expression of VEGF. Ai Zheng, 2006, 25(3): 303―307 (in Chinese)
Bhandari V, Bateman A. Structure and chromosomallocation of the human granulin gene. BiochemBiophys Res Commun, 1992, 188(1): 57―63

doi: 10.1016/0006-291X(92)92349-3
Bateman A, Belcourt D, Bennett H, Lazure C, Solomon S. Granulins, a novel classof peptide from leukocytes. Biochem BiophysRes Commun, 1990, 173(3): 1161―1168

doi: 10.1016/S0006-291X(05)80908-8
Bhandari V, Giaid A, Bateman A. The complementary deoxyribonucleic acid sequence, tissuedistribution, and cellular localization of the rat granulin precursor. Endocrinology, 1993, 133(6): 2682―2689

doi: 10.1210/en.133.6.2682
Sparro G, Galdenzi G, Eleuteri A M, Angeletti M, Schroeder W, Fioretti E. Isolation and N-terminal sequence of multiple forms ofgranulins in human urine. Protein ExprPurif, 1997, 10(2): 169―174

doi: 10.1006/prep.1997.0726
Zhang H, Serrero G. Inhibition of the tumorigenicityof the teratoma PC cell line by transfection with antisense cDNA forPC cell-derived growth factor (PCDGF, epithelin/granulin precursor). Proc Natl Acad Sci USA, 1998, 95(24): 14202―14207

doi: 10.1073/pnas.95.24.14202
Lu R, Serrero G. Inhibition of PC cell-derivedgrowth factor (PCDGF, epithelin/granulin precursor) expression byantisense PCDGF cDNA transfection inhibits tumorigenicity of the humanbreast carcinoma cell line MDA-MB-468. Proc Natl Acad Sci USA, 2000, 97(8): 3993―3998

doi: 10.1073/pnas.97.8.3993
Lu R, Serrero G. Mediation of estrogen mitogeniceffect in human breast cancer MCF-7 cells by PC cell-derived growthfactor (PCDGF/granulin precursor). ProcNatl Acad Sci USA, 2001, 98(1): 142―147

doi: 10.1073/pnas.011525198
Lu R, Serrero G. Stimulation of PC cell-derivedgrowth factor (epithelin/granulin precursor) expression by estradiolin human breast cancer cells. Biochem BiophysRes Commun, 1999, 256(1): 204―207

doi: 10.1006/bbrc.1999.0253
Moriya T, Kanomata N, Kozuka Y, Fukumoto M, Iwachido N, Hata S, Takahashi Y, Miura H, Ishida K, Watanabe M. Usefulnessof immunohistochemistry for differential diagnosis between benignand malignant breast lesions. Breast Cancer, 2009, 16(3): 173―178

doi: 10.1007/s12282-009-0127-7
Hosaka N, Ryu T, Cui W, Li Q, Nishida A, Miyake T, Takaki T, Inaba M, Ikehara S. Relationshipof p53, Bcl-2, Ki-67 index and E-cadherin expression in early invasivebreast cancers with comedonecrosis as an accelerated apoptosis. J Clin Pathol, 2006, 59(7): 692―698

doi: 10.1136/jcp.2005.030296
Liau L M, Lallone R L, Seitz R S, Buznikov A, Gregg J P, Kornblum H I, Nelson S F, Bronstein J M. Identification of a humanglioma-associated growth factor gene, granulin, using differentialimmuno-absorption. Cancer Res, 2000, 60(5): 1353―1360
He Z, Bateman A. Progranulin gene expressionregulates epithelial cell growth and promotes tumor growth in vivo. Cancer Res, 1999, 59(13): 3222―3229
Naeem M, Nasir A, Aman Z, Ahmad T, Samad A. Frequency of HER-2/neu receptor positivityand its association with other features of breast cancer. J Ayub Med Coll Abbottabad, 2008, 20(3): 23―26
Vinothini G, Murugan R S, Nagini S. Evaluation of molecular markers in a rat model of mammarycarcinogenesis. Oncol Res, 2009, 17(10): 483―493

doi: 10.3727/096504009789735459
Carlsson J, Soussi T, Persson B. Investigation and prediction of the severity of p53 mutantsusing parameters from structural calculations. FEBS J, 2009, 276(15): 4142―4155

doi: 10.1111/j.1742-4658.2009.07124.x
Vinothini G, Murugan R S, Nagini S. Evaluation of molecular markers in a rat model of mammarycarcinogenesis. Oncol Res, 2009, 17(10): 483―493

doi: 10.3727/096504009789735459
Seewaldt V L, Mrózek K, Sigle R, Dietze E C, Heine K, Hockenbery D M, Hobbs K B, Caldwell L E. Suppression of p53 functionin normal human mammary epithelial cells increases sensitivity toextracellular matrix-induced apoptosis. J Cell Biol, 2001, 155(3): 471―486

doi: 10.1083/jcb.200011001
Sivaraman L, Conneely O M, Medina D, O'Malley B W. p53 is a potential mediator of pregnancy and hormone-induced resistanceto mammary carcinogenesis. PNAS, 2001, 98(22): 12379―12384

doi: 10.1073/pnas.221459098
Shilkaitis A, Green A, Punj V, Steele V, Lubet R, Christov K. Dehydroepiandrosterone inhibits the progression phaseof mammary carcinogenesis by inducing cellular senescence via a p16-dependentbut p53-independent mechanism. Breast CancerRes, 2005, 7(6): R1132―R1140

doi: 10.1186/bcr1350
Hirsch F R, Scagliotti G V, Langer C J, Varella-Garcia M, Franklin W A. Epidermal growth factor familyof receptors in preneoplasia and lung cancer: perspectives for targetedtherapies. Lung Cancer, 2003, 41 Suppl 1: S29―S42

doi: 10.1016/S0169-5002(03)00137-5
Kim J A. Targeted therapies for the treatment of cancer, Am J Surg, 2003, 186(3): 264―268

doi: 10.1016/S0002-9610(03)00212-5
Murphy C G, Modi S. HER2 breast cancer therapies:a review. Biologics, 2009, 3: 289―301
Martín-Orozco R M, Almaraz-Pro C, Rodríguez-Ubreva F J, Cortés M A, Ropero S, Colomer R, López-Ruiz P, Colás B. EGFprevents the neuroendocrine differentiation of LNCaP cells inducedby serum deprivation: the modulator role of PI3K/Akt. Neoplasia, 2007, 9(8): 614―624

doi: 10.1593/neo.07337
[1] Xin Wu, Xiaobao Sheng, Rong Sheng, Hongjuan Lu, Huji Xu. Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis[J]. Front. Med., 2019, 13(4): 411-419.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed